Skip to content
2000
Volume 21, Issue 15
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Lower urinary tract symptoms (LUTS) secondary to benign prostate obstruction (BPO) afflict a very large part of the population on a global scale. Urologists confront patients with a diversity of BPH-related symptoms in their daily practice. For years, the cornerstone of obstructive BPH treatment consisted of mostly medical and to a lesser extent surgical therapies. However, while medical treatment has come to a standstill, over the last decade, new minimally invasive surgical therapies (MISTs) have emerged, conferring several possible advantages over conventional transurethral resection of the prostate (TURP). MISTs have also demonstrated the ability to better respect and preserve sexual function while providing safety and minimal morbidity. Their long-term efficacy and durability over drug therapy remain debatable, as is the need for secondary procedures. In the present paper, we aim to offer a narrative summary of the available literature, thus providing an indirect comparative assessment of drugs and MISTs for obstructive LUTS.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450121666200630111723
2020-12-01
2025-04-18
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450121666200630111723
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test